<DOC>
	<DOCNO>NCT01680328</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial ass describe pain relation subcutaneous ( skin ) injection different combination injection speed volume respect acceptance injection pain backflow .</brief_summary>
	<brief_title>Investigation Pain During Subcutaneous Injections With Different Injection Speed Volume Combinations</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>Informed consent obtain trialrelated activity . Type 1 type 2 diabetes Daily injection ( ) antidiabetic drug ( insulin Glucagon like Peptide1 ( GLP1 ) analogues ) via peninjector vial/syringe 6 month Body mass index ( BMI ) 18.5 30.0 kg/m^2 ( include ) Caucasians Known suspect hypersensitivity needle , ink ball pen contact injection area clinical visit Previous participation trial . Participation define : screen Receipt investigational medicinal product influence pain perception within 14 day screen Injection 40 unit insulin per injection Continuous Subcutaneous Insulin Infusion use within last 6 month Continuous Glucose Monitoring use within last 6 month Intake painrelieving analgesic within last week ( exclude low dose aspirin cardio vascular prophylactic dos ) Known active inactive skin disease injection area may affect pain perception Anticoagulant treatment within last month ( low dose aspirin cardiovascular prophylactic dos allow . However , day injection )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>